Symphony Health, a research firm, recently released a report regarding EXPAREL sales and volume for the August estimates. The report stated that the estimate for EXPAREL volume went down around 2.6% on month-over-month basis in August 2015. In relation to this, the analysts at Webbush, Kelechi Chikere and Liana Moussatos took a peep into the situation of Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Even though the sales and volume data has slightly put off the shares of this company, but despite this meltdown, the Q3 2015 of Pacira Pharmaceuticals seems to be on the right path.

The details

According to Symphony Health data, the sales as well as volumes of the company have both, dropped down in comparison to July 2015, apart from the pain treatments of the hospital. Decreasing Pacira Pharmaceuticals Inc volume is indicating a temporary decrease in the procedures that are elective in nature, and this is mainly because of the vacations. The consensus for company’s third quarter sales is $58.2 million, which according to the analysts, is trailing the right path.

Is Symphony Health report reliable?

Despite being the established research firm, Wedbush seems to remain sceptical of its reliability as far as this report goes. This is so because Symphony Health has collected this data over a wider spectrum, i.e., from 68.5% to 108%of the EXPAREL sales. Wedbush is therefore cautious, especially because it knows the way this data is gathered as well as audited by the SH.

Repercussions of the slow EXPAREL growth

According to the analysts, a slow and steady growth in EXPAREL volume and sales should make the management cautious. However, having said that, the team of the company is anticipating a flat Q3 2015 in comparison to the second quarter. The fourth quarter seems rosy for the company, where the analysts expect the faster net growth as far as the sales are concerned, because of strong season.

SH shall be releasing the EXPAREL volume and sales data for the month of September on 2 October 2015.